Browse By: Country ι Category ι Tag

Partnering Terms And Agreements Market Research Reports

Global Big Pharma Partnering Terms and Agreements 2010-2017: Deal trends, players and financials
This report provides details of the latest Big Pharma agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals. The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader
Published Date: Apr 2017
Published By: Current Partnering

Price: $2995
Global Medical Device Partnering Terms and Agreements 2010-2017: Deal trends, players and financials
This report provides details of the latest Medical Device agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review Medical Device deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Medical Device partnering deals. The report presents financial deal term values for Medical Device deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Medical Device partnering field; both the leading deal values and most active Medical Device dealmaker companies are repo
Published Date: Apr 2017
Published By: Current Partnering

Price: $2995
Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017
The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest discovery agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail
Published Date: Apr 2017
Published By: Current Partnering

Price: $2995
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017
This report provides details of the latest preclinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of over 2,000 preclinical stage partnering deals announced since 2010 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclo
Published Date: Apr 2017
Published By: Current Partnering

Price: $2995
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of over 2,000 clinical stage partnering deals announced since 2010 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted
Published Date: Apr 2017
Published By: Current Partnering

Price: $2995
Global Antibiotics Partnering Terms and Agreements 2010 to 2017
Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Antibiotics partnering contract documents Top antibiotics deals by value The Global Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes
Published Date: Apr 2017
Published By: Current Partnering

Price: $2995
Global Gene Therapy Partnering Terms and Agreements 2010 to 2017
Trends in gene therapy partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Gene therapypartnering contract documents Top gene therapy deals by value The Global Gene Therapy Partnering Terms and Agreements 2010-2017 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commerci
Published Date: Apr 2017
Published By: Current Partnering

Price: $2995
Global Biomarker Partnering Terms and Agreements 2010-2017: Deal trends, players and financials
Trends in biomarker partnering deals Biomarker partnering agreement structure Biomarker partnering contract documents Top biomarker deals by value Most active biomarker dealmakers The Global Biomarker Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest Biomarker agreements announced in the healthcare sectors. A biomarker, or biological
Published Date: Apr 2017
Published By: Current Partnering

Price: $2995
Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2017
This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2010 to 2017. For pharmaceutical and biotechnology professionals, the report supplies a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in t
Published Date: Feb 2017
Published By: Current Partnering

Price: $2995
Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
The report provides a detailed understanding and analysis of how and why companies enter business, royalty financing agreements. The focus of the report is on partnerships for royalty assets where partners have entered an agreement to dispose of or acquire said assets. The report provides access to royalty financing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product Revenue assets – also known as ‘synthetic royalties’, where a specialist investment company acquires the rights to a proportion of future revenue streams in retu
Published Date: Feb 2017
Published By: Current Partnering

Price: $1995
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2010. There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments. Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount h
Published Date: Feb 2017
Published By: Current Partnering

Price: $1995
Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2017
This report provides details of the latest Co-development agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of Co-development agreements from 2010 to 2017. There is an increasing willingness for parties to enter co-development deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments. Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another pa
Published Date: Feb 2017
Published By: Current Partnering

Price: $2995
Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2017
This report provides details of the latest collaborative R&D deals announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date with the latest information, the report provides details of collaborative R&D deals from 2012 to 2017. There has been a long standing willingness for parties to enter collaborative R&D deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages. Collaborative R&D is a specific type of partnering deal whereby the parties to the deal agree to collaborate on the research and development and subsequently commercialize a compound, product or technology. There are several forms of a collaborative R&D deal; A tr
Published Date: Feb 2017
Published By: Current Partnering

Price: $2995
Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017
The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest Pharmacogenomics agreements announced in the healthcare sectors. Pharmacogenomics focusses on the influence of genetic variation on drug response in patients by correlating gene expression or single nucleotide polymorphisms with a drug’s efficacy or toxicity. Understanding the flexibility of a prospective partner’s negotiated deals terms provide
Published Date: Feb 2017
Published By: Current Partnering

Price: $2995
Global Bioinformatics Partnering Terms and Agreements 2010 to 2017
Trends in bioinformatics partnering deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active deal makers Financial deal terms for bioinformatics The Global Bioinformatics Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborati
Published Date: Feb 2017
Published By: Current Partnering

Price: $2995
Global Diagnostic Imaging Partnering Terms and Agreements 2010 to 2017
The report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging partnering deals. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering: Imaging CT Endoscope Molecular and nuclear PET SPECT MRI Ultrasound X ray Angiography Fluoroscopy Mammography This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2010. This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2010. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus. Eac
Published Date: Feb 2017
Published By: Current Partnering

Price: $2995
Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2017
Comprehensive directory of personalized medicine in oncology deals since 2010 Personalized medicine in oncology contract documents Personalized medicine in oncology agreement terms Personalized medicine in oncology agreement structure Top personalized medicine in oncology deals by value Most active personalized medicine in oncology dealmakers The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are di
Published Date: Feb 2017
Published By: Current Partnering

Price: $2995
Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials
The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest antibody agreements announced in the healthcare sectors, covering: Antibodies Antibody-drug conjugates Monoclonal antibodies Murine mAb Chimeric mAb Humanized mAb Human aAb Polyclonal Antibodies Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect
Published Date: Nov 2016
Published By: Current Partnering

Price: $2995
Global Vaccine Partnering Terms and Agreements 2010-2016: Deal trends, players and financials
Trends in vaccine and adjuvant partnering deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for vaccines This report contains a comprehensive listing of all vaccine partnering deals announced since January 2010, including financial terms where available, including over 1,000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currentl
Published Date: Nov 2016
Published By: Current Partnering

Price: $2995
Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016
The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest discovery agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail
Published Date: Oct 2016
Published By: Current Partnering

Price: $2995

Upcoming Reports

Wheelchair Accessible Vehicle Converters Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
Vehicles which are converted in a way that have easy access for wheelchairs are termed as wheelchair accessible vehicles or WAV’s. The vehicles are specially converted from a standard vehicle to WAV in order to accommodate the wheelchair. Wheelchair accessible vehicles are considered as mult
Published By: Transparency
Price: $5795
Enteral Nutrition Pumps Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
Enteral nutrition pumps also known as enteral feeding pumps are used to deliver nutritious foods containing carbohydrate, protein, fat, vitamin, minerals and water by inserting directly into the stomach or parts of small intestine. Enteral nutrition pumps are recommended to patients suffering from
Published By: Transparency
Price: $5795
Residential Water Treatment Equipment Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2014 - 2020
Increasing industrial and environmental pollution around the world is increasing the need for water treatment. Water pollution due to increasing industrialization and environment pollution is leading to death and spread of diseases. It also adversely affects more than 1 billion of population every
Published By: Transparency
Price: $5795
Steam Boiler System Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth and Forecast 2014 - 2020
The growing need of effective heating systems as well as the requirement of increasing operating efficiency of residential and commercial complexes has led to the widespread adoption of steam boiler systems. This technology provides high steam temperature and improved pressure parameters to achiev
Published By: Transparency
Price: $5795
Seismic Survey Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth and Forecast 2014 - 2020
Increasing exploration activities owing to the efforts of oil and gas companies to locate new oil and gas reserves is expected to drive the global seismic survey market during the forecast period. Oil and gas companies use seismic surveys to map and interpret potential petroleum reserves.  P
Published By: Transparency
Price: $5795

Back To Top